专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170218451A1 METHOD OF TREATING, OR AT LEAST INHIBITING THE ONSET OF, URATE TRANSPORT FAILURE 审中-公开
公开(公告)号：US20170218451A1
公开(公告)日：2017-08-03
申请号：US15486788
申请日：2017-04-13
申请人： HIROTAKA MATSUO , NARIYOSHI SHINOMIYA , TAKAHIRO NAKAMURA , THE UNIVERSITY OF TOKYO , TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES
发明人： HIROTAKA MATSUO , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： C12Q1/68 , A61K38/17
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： Methods of treating, or at least inhibiting the onset of, urate transport failure are provided. The methods can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

2. 发明授权

US07968762B2 Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) 有权
标题翻译：表达人肝细胞生长因子（hHGF）的免疫受损转基因小鼠
公开(公告)号：US07968762B2
公开(公告)日：2011-06-28
申请号：US11571947
申请日：2005-07-12
申请人： George F. Vande Woude , Yu-wen Zhang , Nariyoshi Shinomiya
发明人： George F. Vande Woude , Yu-wen Zhang , Nariyoshi Shinomiya
IPC分类号： A01K67/027 , A01K67/00 , A01K67/033 , G01N33/00 , C12N15/00
CPC分类号： A01K67/0271 , A01K67/0275 , A01K2217/052 , A01K2217/15 , A01K2217/203 , A01K2217/206 , A01K2227/105 , A01K2267/01 , A01K2267/0331 , C07K14/4753 , C12N15/8509
摘要： A transgenic animal model for evaluating growth, survival and/or metastasis of xenotransplanted normal or tumor cells or tissue is disclosed, in which a human growth factor, hHGF stimulates growth in vivo of human cells or tissue. A strain of Tg mice on the C3H background that is immunocompromised as a result of a homozygous scid gene has been bred which express a nucleic acid encoding hHGF/SE The ectopically expressed hHGF/SF ligand significantly enhances growth of human tumor cell lines and explanted tumor cells or tissue that express the Met receptor for hHGF. Such animals also have an enlarged normal livers and greater than normal liver regenerative capacity. Any Met-expressing hHGF-dependent human cells, including hepatocytes and various stem cells can survive and grow in such animals.
摘要翻译：公开了用于评估异种移植的正常或肿瘤细胞或组织的生长，存活和/或转移的转基因动物模型，其中人生长因子hHGF刺激人细胞或组织的体内生长。已经培育了作为纯合scid基因的免疫受损的C3H背景上的Tg小鼠的菌株，其表达编码hHGF / SE的核酸。异位表达的hHGF / SF配体显着增强人肿瘤细胞系和外植体肿瘤的生长表达hHGF的Met受体的细胞或组织。这样的动物也具有扩大的正常肝脏并且大于正常的肝脏再生能力。任何Met表达的hHGF依赖性人细胞，包括肝细胞和各种干细胞都可以在这样的动物中存活和生长。

3. 发明授权

US07872117B2 c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity 有权
标题翻译： c-met siRNA腺病毒载体抑制癌细胞生长，侵袭和致瘤性
公开(公告)号：US07872117B2
公开(公告)日：2011-01-18
申请号：US10599327
申请日：2005-03-28
申请人： Nariyoshi Shinomiya , George F. Vande Woude
发明人： Nariyoshi Shinomiya , George F. Vande Woude
IPC分类号： C07H21/04 , C12N15/00 , A61K31/70
CPC分类号： C12N15/1135 , C12N2310/111 , C12N2310/14 , C12N2799/022
摘要： Suppression of the Hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth. Using RNA interference (RNAi) technology and adenoviruses carrying siRNA (Ad Met siRNA) target sequences dramatically reduced Met expression in mouse, dog and human tumor cells. Met was suppressed using Ad Met siRNA in mouse mammary tumor (DA3) cells and Met-transformed (NIH3T3 (M114) cells as well as human prostate cancer, sarcoma, glioblastoma, gastric and ovarian cancer cells. Furthermore, the Ad Met siRNA infection reversed transformed cell morphology. Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering as well as ligand-mediated invasion activity and growth of tumor cells. Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA triggered apoptosis was correlated to suppressed tumorigenicity in vivo. Intro-tumoral infection with c-met siRNA adenovirus vectors produced significant reduction in tumor growth. Thus Met RNAi is an effective weapon for targeting Met expression and for treating c-Met+ cancers.
摘要翻译：通过靶向Met蛋白酪氨酸激酶抑制肝细胞生长因子/分散因子（HGF / SF）-Met信号通路被测试作为抑制肿瘤生长的策略。使用RNA干扰（RNAi）技术和携带siRNA（Ad Met siRNA）靶序列的腺病毒大大降低了小鼠，狗和人类肿瘤细胞中的Met表达。 Met在小鼠乳腺肿瘤（DA3）细胞和Met转化的（NIH3T3（M114）细胞以及人类前列腺癌，肉瘤，成胶质细胞瘤，胃癌和卵巢癌细胞中使用Ad Met siRNA进行抑制，此外，Ad Met siRNA感染逆转 Ad Met siRNA通过诱导凋亡来杀死癌细胞，RNAi靶向Met抑制HGF / SF介导的散射以及配体介导的侵袭活性和肿瘤细胞的生长Met siRNA感染也消除下游Met信号转导到分子，如 Akt和p44 / 42 MAPK。重要的是，Met siRNA引发的细胞凋亡与体内抑制的致瘤性相关，c-met siRNA腺病毒载体的肿瘤内感染导致肿瘤生长显着降低，因此Met RNAi是靶向Met的有效武器表达和治疗c-Met +癌症。

4. 发明申请

US20070232555A1 C-Met Sirna Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion and Tumorigenicity 有权
标题翻译： C-Met Sirna腺病毒载体抑制癌细胞生长，侵袭和致瘤性
公开(公告)号：US20070232555A1
公开(公告)日：2007-10-04
申请号：US10599327
申请日：2005-03-28
申请人： Nariyoshi Shinomiya , George Woude
发明人： Nariyoshi Shinomiya , George Woude
IPC分类号： A61K31/7052 , C07H21/02 , C12N15/00
CPC分类号： C12N15/1135 , C12N2310/111 , C12N2310/14 , C12N2799/022
摘要： Suppression of the Hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth. Using RNA interference (RNAi) technology and adenoviruses carrying siRNA (Ad Met siRNA) target sequences dramatically reduced Met expression in mouse, dog and human tumor cells. Met was suppressed using Ad Met siRNA in mouse mammary tumor (DA3) cells and Met-transformed (NIH3T3 (M114) cells as well as human prostate cancer, sarcoma, glioblastoma, gastric and ovarian cancer cells. Furthermore, the Ad Met siRNA infection reversed transformed cell morphology. Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering as well as ligand-mediated invasion activity and growth of tumor cells. Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA triggered apoptosis was correlated to suppressed tumorigenicity in vivo. Intro-tumoral infection with c-met siRNA adenovirus vectors produced significant reduction in tumor growth. Thus Met RNAi is an effective weapon for targeting Met expression and for treating c-Met+ cancers.
摘要翻译：通过靶向Met蛋白酪氨酸激酶抑制肝细胞生长因子/分散因子（HGF / SF）-Met信号通路被测试作为抑制肿瘤生长的策略。使用RNA干扰（RNAi）技术和携带siRNA（Ad Met siRNA）靶序列的腺病毒大大降低了小鼠，狗和人类肿瘤细胞中的Met表达。 Met在小鼠乳腺肿瘤（DA3）细胞和Met转化的（NIH3T3（M114）细胞以及人类前列腺癌，肉瘤，成胶质细胞瘤，胃癌和卵巢癌细胞中使用Ad Met siRNA进行抑制，此外，Ad Met siRNA感染逆转 Ad Met siRNA通过诱导凋亡来杀死癌细胞，RNAi靶向Met抑制HGF / SF介导的散射以及配体介导的侵袭活性和肿瘤细胞的生长Met siRNA感染也消除下游Met信号转导到分子，如 Akt和p44 / 42 MAPK。重要的是，Met siRNA引发的细胞凋亡与体内抑制的致瘤性相关，c-met siRNA腺病毒载体的肿瘤内感染导致肿瘤生长显着降低，因此Met RNAi是靶向Met的有效武器表达和治疗c-Met 癌症。

5. 发明申请

US20150080257A1 METHOD FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR 审中-公开
标题翻译：评估尿酸运输相关疾病因子和与炎症相关疾病因子的方法
公开(公告)号：US20150080257A1
公开(公告)日：2015-03-19
申请号：US14542633
申请日：2014-11-16
申请人： HIROTAKA MATSUO , NARIYOSHI SHINOMIYA , TAKAHIRO NAKAMURA , THE UNIVERSITY OF TOKYO , TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES
发明人： HIROTAKA MATSUO , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F2085, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译：提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。当受试者具有V12M，R113X，Q126X，Q141K，F2085，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够诱导尿酸盐运输失败，或归因于该失败的状态或疾病。当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化，所述变异与其他SNP的连锁不平衡有关。

6. 发明申请

US20120255044A1 URATE TRANSPORTER, AS WELL AS METHOD AND KIT FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR, AND TEST SAMPLE AND DRUG 有权
标题翻译： URATE TRANSPORTER，作为评估与运输相关的疾病因素和与炎症有关的疾病因素和测试样品和药物的方法和工具包
公开(公告)号：US20120255044A1
公开(公告)日：2012-10-04
申请号：US13379346
申请日：2010-06-22
申请人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
发明人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： C12Q1/68 , G01N21/64 , C40B40/06 , A01K67/027 , C12N5/10 , C12N1/00 , C07H21/04 , C40B30/04
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译：提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。当受试者具有V12M，R113X，Q126X，Q141K，F208S，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够诱导尿酸盐运输失败，或归因于该失败的状态或疾病。当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化，所述变异与其他SNP的连锁不平衡有关。

7. 发明申请

US20080196110A1 Immune-Compromised Transgenic Mice Expressing Human Hepatocyte Growth Factor (Hhgf) 有权
标题翻译：表达人类肝细胞生长因子（hHGF）的免疫缺陷型转基因小鼠
公开(公告)号：US20080196110A1
公开(公告)日：2008-08-14
申请号：US11571947
申请日：2005-07-12
申请人： George F. Vande Woude , Yu-wen Zhang , Nariyoshi Shinomiya
发明人： George F. Vande Woude , Yu-wen Zhang , Nariyoshi Shinomiya
IPC分类号： G01N33/53 , A01K67/027 , C12N15/00 , C12P21/00 , C12N5/06
CPC分类号： A01K67/0271 , A01K67/0275 , A01K2217/052 , A01K2217/15 , A01K2217/203 , A01K2217/206 , A01K2227/105 , A01K2267/01 , A01K2267/0331 , C07K14/4753 , C12N15/8509
摘要： A transgenic animal model for evaluating growth, survival and/or metastasis of xenotransplanted normal or tumor cells or tissue is disclosed, in which a human growth factor, hHGF stimulates growth in vivo of human cells or tissue. A strain of Tg mice on the C3H background that is immunocompromised as a result of a homozygous scid gene has been bred which express a nucleic acid encoding hHGF/SE The ectopically expressed hHGF/SF ligand significantly enhances growth of human tumor cell lines and explanted tumor cells or tissue that express the Met receptor for hHGF. Such animals also have an enlarged normal livers and greater than normal liver regenerative capacity. Any Met-expressing hHGF-dependent human cells, including hepatocytes and various stem cells can survive and grow in such animals.
摘要翻译：公开了用于评估异种移植的正常或肿瘤细胞或组织的生长，存活和/或转移的转基因动物模型，其中人生长因子hHGF刺激人细胞或组织的体内生长。已经培育了作为纯合scid基因的免疫受损的C3H背景上的Tg小鼠的菌株，其表达编码hHGF / SE的核酸。异位表达的hHGF / SF配体显着增强人肿瘤细胞系和外植体肿瘤的生长表达hHGF的Met受体的细胞或组织。这样的动物也具有扩大的正常肝脏并且大于正常的肝脏再生能力。任何Met表达的hHGF依赖性人细胞，包括肝细胞和各种干细胞都可以在这样的动物中存活和生长。

8. 发明授权

US08940286B2 Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug 有权
标题翻译：尿酸转运蛋白，以及评估尿酸运输相关疾病因子和炎症相关疾病因子的方法和试剂盒，以及测试样品和药物
公开(公告)号：US08940286B2
公开(公告)日：2015-01-27
申请号：US13379346
申请日：2010-06-22
申请人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
发明人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： A61K48/00 , A61K38/00 , C07K14/47 , C07K14/705 , G01N33/566 , G01N33/68
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译：提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。当受试者具有V12M，R113X，Q126X，Q141K，F208S，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够诱导尿酸盐运输失败，或归因于该失败的状态或疾病。当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化，所述变异与其他SNP的连锁不平衡有关。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式